Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Expected to Announce Earnings of -$0.73 Per Share

Equities research analysts expect Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) to report earnings per share (EPS) of ($0.73) for the current quarter, Zacks Investment Research reports. Six analysts have made estimates for Enanta Pharmaceuticals’ earnings. The lowest EPS estimate is ($1.59) and the highest is $1.99. Enanta Pharmaceuticals posted earnings of ($0.55) per share during the same quarter last year, which suggests a negative year-over-year growth rate of 32.7%. The company is expected to report its next earnings report on Monday, November 22nd.

According to Zacks, analysts expect that Enanta Pharmaceuticals will report full year earnings of ($3.88) per share for the current financial year, with EPS estimates ranging from ($4.28) to ($2.69). For the next financial year, analysts anticipate that the company will report earnings of ($4.73) per share, with EPS estimates ranging from ($7.02) to ($1.67). Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that follow Enanta Pharmaceuticals.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings data on Thursday, August 5th. The biotechnology company reported ($1.19) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.41) by $0.22. Enanta Pharmaceuticals had a negative return on equity of 14.86% and a negative net margin of 86.21%. The firm had revenue of $21.62 million during the quarter, compared to analyst estimates of $21.87 million.

A number of equities analysts recently commented on the company. Jefferies Financial Group began coverage on Enanta Pharmaceuticals in a research note on Wednesday, October 6th. They set a “buy” rating and a $95.00 price target for the company. JMP Securities upped their price objective on Enanta Pharmaceuticals from $70.00 to $77.00 and gave the company an “outperform” rating in a research report on Friday, August 6th. Zacks Investment Research upgraded Enanta Pharmaceuticals from a “hold” rating to a “buy” rating and set a $79.00 price objective on the stock in a research report on Monday. SVB Leerink began coverage on Enanta Pharmaceuticals in a research report on Thursday, September 9th. They set a “market perform” rating and a $55.00 price objective on the stock. Finally, Royal Bank of Canada decreased their price objective on Enanta Pharmaceuticals from $52.00 to $50.00 and set a “sector perform” rating on the stock in a research report on Friday, August 6th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, Enanta Pharmaceuticals presently has an average rating of “Hold” and an average target price of $68.50.

Enanta Pharmaceuticals stock traded up $1.83 during midday trading on Thursday, reaching $71.47. 1,305 shares of the stock traded hands, compared to its average volume of 144,282. The stock’s fifty day moving average is $55.88 and its 200-day moving average is $50.29. Enanta Pharmaceuticals has a 12 month low of $40.32 and a 12 month high of $72.00. The stock has a market cap of $1.44 billion, a P/E ratio of -17.18 and a beta of 0.43.

In related news, CEO Jay R. Luly sold 4,516 shares of the stock in a transaction that occurred on Wednesday, September 15th. The stock was sold at an average price of $59.06, for a total value of $266,714.96. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, VP Nathalie Adda sold 4,047 shares of the stock in a transaction on Monday, October 11th. The shares were sold at an average price of $70.34, for a total value of $284,665.98. The disclosure for this sale can be found here. Over the last quarter, insiders sold 22,016 shares of company stock worth $1,494,302. Company insiders own 11.74% of the company’s stock.

Several institutional investors have recently bought and sold shares of the company. The PNC Financial Services Group Inc. raised its stake in Enanta Pharmaceuticals by 42.8% in the 1st quarter. The PNC Financial Services Group Inc. now owns 787 shares of the biotechnology company’s stock worth $39,000 after acquiring an additional 236 shares during the last quarter. Fisher Asset Management LLC raised its stake in Enanta Pharmaceuticals by 4.1% in the 2nd quarter. Fisher Asset Management LLC now owns 6,601 shares of the biotechnology company’s stock worth $291,000 after acquiring an additional 258 shares during the last quarter. State of Alaska Department of Revenue raised its stake in Enanta Pharmaceuticals by 2.3% in the 2nd quarter. State of Alaska Department of Revenue now owns 12,435 shares of the biotechnology company’s stock worth $547,000 after acquiring an additional 282 shares during the last quarter. Virtus ETF Advisers LLC raised its stake in Enanta Pharmaceuticals by 2.8% in the 1st quarter. Virtus ETF Advisers LLC now owns 14,721 shares of the biotechnology company’s stock worth $726,000 after acquiring an additional 400 shares during the last quarter. Finally, Shell Asset Management Co. raised its stake in Enanta Pharmaceuticals by 5.7% in the 2nd quarter. Shell Asset Management Co. now owns 8,914 shares of the biotechnology company’s stock worth $392,000 after acquiring an additional 480 shares during the last quarter.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases.

Read More: Why do corrections happen?

Get a free copy of the Zacks research report on Enanta Pharmaceuticals (ENTA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Enanta Pharmaceuticals (NASDAQ:ENTA)

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.